Video

Dr. Borgen on Disconnect Between Practitioners on the USPSTF Breast Cancer Screening Guidelines

Related Videos
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Vered Stearns, MD
Kevin Kalinsky, MD, MS
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
David Rimm, MD, PhD
Related Content
Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com
December 12th 2024

Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
December 12th 2024

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Breast cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 11th 2024

Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer

Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer
December 11th 2024

Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer